Close Menu

NEW YORK – Infectious disease diagnostics company MeMed said on Tuesday that it has received the CE-IVD mark for its MeMed BV diagnostic test and its point-of-care MeMed Key platform.

With the clearance MeMed can begin offering the BV test at the point of care. The test measures a set of three host-response proteins to help distinguish between bacterial and viral infections and guide antibiotic use.

The company already offered a CE-IVD-marked ELISA version of the test.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

Amid the COVID-19 pandemic, hospitals and intensive care units around the world have been overwhelmed by unprecedented levels of demand. 

Sponsored by
LGC SeraCare Life Sciences

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.

Sponsored by

This webinar will present the details of a COVID-19 saliva screening program that has been implemented at more than 90 different colleges, universities, private schools, and nursing homes across New York state.